ACRV Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
18.7M
-6.2%
19.9M
-1.1%
20.1M
+2.2%
19.7M
-13.1%
22.6M
R&D
13.8M
-8.7%
15.2M
+2.8%
14.7M
+8.0%
13.6M
-15.7%
16.2M
SG&A
4.8M
+1.9%
4.7M
-11.8%
5.4M
-11.1%
6.0M
-6.6%
6.5M
Operating Income
-18668000
+6.2%
-19902000
+1.1%
-20116000
-2.2%
-19687000
+13.1%
-22649000
EBITDA
-18263000
+6.4%
-19519000
+1.2%
-19755000
-2.2%
-19338000
+13.3%
-22314000
Net Income
-17964000
+5.7%
-19042000
-0.3%
-18985000
-4.1%
-18234000
+13.2%
-21006000
EPS (Basic)
$-0.43
+12.2%
$-0.49
+0.0%
$-0.49
-4.3%
$-0.47
+14.5%
$-0.55
EPS (Diluted)
$-0.43
+12.2%
$-0.49
+0.0%
$-0.49
-4.3%
$-0.47
+14.5%
$-0.55
Shares (Diluted)
41.8M
+8.0%
38.7M
+0.2%
38.7M
+0.3%
38.6M
+0.3%
38.5M
Acrivon Therapeutics (ACRV) โ€” Financials